ArticleInternational health2023
Lassa fever cases suffer from severe underreporting based on reported fatalities.
Article in International health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Lassa fever in West Africa: a systematic review and meta-analysis of attack rates, case fatality rates and risk factors.BMC public health · 2025Pooled it
- Efficacy, safety, and immunogenicity of Lassa fever vaccines: A living systematic review and landscape analysis of vaccine candidates.PloS one · 2025Pooled it
- Local Knowledge of Land Use Effects on Human-Rodent Interfaces in Lassa-Endemic Nigeria.EcoHealth · 2026Article
- The socio-economic shield limits Lassa virus spillover in urban West Africa.Epidemiology and infection · 2026Article
- Fractional-order modeling and optimal control of lassa fever with non-pharmaceutical interventions.MethodsX · 2026Article
- Local heterogeneity in Lassa fever serology in rural Nigeria: Implications for vaccine trial site selection.PLoS neglected tropical diseases · 2026Article
- B cell immunity to the Lassa virus glycoprotein is a correlate of vaccination-induced virus control in mice.Nature communications · 2026Article
- Review
- Land use gradients drive spatial variation in Lassa fever host communities in the Eastern Province of Sierra Leone.The Journal of animal ecology · 2026Article
- Genomic epidemiology and evolutionary analysis of Lassa virus from small mammals suggest bidirectional viral movement across humans and animals.Virus evolution · 2026Article
- Serosurveillance Identifies an Endemic Hotspot of Lassa Fever in Faranah, Upper Guinea.The Journal of infectious diseases · 2025Article
- Evaluation of antigen and antibody assays for surveillance of Lassa virus in peri-domestic rodents in southeastern Sierra Leone: a cross-sectional study.The Lancet. Microbe · 2025Article
- Robust polyfunctional CD8The Journal of general virology · 2025Article
- Safety Toxicology Study of Reassortant Mopeia-Lassa Vaccine in Guinea Pigs.Future pharmacology · 2025Article
- Molecular cloning and host range analysis of three cytomegaloviruses fromJournal of virology · 2025Article
- Safety, immunogenicity, efficacy, and effectiveness of Lassa fever vaccines in pregnant persons, children, and adolescents: a protocol for a living systematic review and meta-analysis.Reproductive health · 2025Article
- Estimating the burden of mpox among MSM in South Africa.BMJ global health · 2025Article
- Lassa virus in novel hosts: insights into the epidemiology of lassa virus infections in southern Nigeria.Emerging microbes & infections · 2024Article
- Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates.Emerging microbes & infections · 2024Article
- Health and economic impacts of Lassa vaccination campaigns in West Africa.Nature medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundLassa fever is a viral haemorrhagic fever endemic to eight West African countries. Symptomatic disease is expected to occur in 20% of those infected and transmission typically occurs from viral spillover from rodent hosts. The combination of limited access to diagnostics and healthcare means the true burden of this disease is unknown.
methodsThe case fatality rate among confirmed, probable and possible cases of Lassa fever in endemic regions is expected to be ≈15%. Here, annual reported cases and deaths have been used to estimate the case fatality rate, using three subsets of available data, to understand the scale of underreporting of severe human cases.
resultsThe literature review produced 38 records of cases and fatalities, comprising 5230 reported cases and 1482 reported deaths in seven countries. The estimated case fatality rate ranges from 16.5 to 25.6% (standard deviation 11.5-32.2). The expected number of severe cases between 2012 and 2022 is 8995, with current reported numbers 58% of what is expected.
conclusionThis analysis highlights current uncertainty and systemic underreporting of the morbidity and mortality burden of Lassa fever in its endemic region and must be considered when discussing the epidemiology of this neglected tropical disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.